Literature DB >> 17056627

Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands.

Erik H Niks1, Jan B M Kuks, Jan J G M Verschuuren.   

Abstract

The epidemiology of myasthenia gravis subtypes and the frequency of antibodies to muscle-specific kinase (MuSK) was studied in patients with generalised myasthenia gravis without anti-acetylcholine receptor antibodies who had an onset of symptoms between 1990 and 2004 in a well-defined region in The Netherlands. The nationwide prevalence and incidence of myasthenia gravis with anti-MuSK antibodies were also studied. MuSK antibodies were found in 22% of patients with generalised myasthenia gravis without anti-acetylcholine receptor antibodies. Nationwide, 35 patients with MuSK myasthenia gravis were identified, yielding a prevalence of 1.9 per million (95% confidence interval (CI) 1.22 to 2.59) and an annual incidence 0.10 per million person-years (95% CI 0.06 to 0.14).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17056627      PMCID: PMC2077782          DOI: 10.1136/jnnp.2006.102517

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  10 in total

Review 1.  Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese.

Authors:  Jiann-Horng Yeh; Wei-Hung Chen; Hou-Chang Chiu; Angela Vincent
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

Review 2.  Genetic factors in pemphigus.

Authors:  François Tron; Danièle Gilbert; Hugo Mouquet; Pascal Joly; Laurent Drouot; Sondès Makni; Hatem Masmoudi; Dominique Charron; Mondher Zitouni; Pascale Loiseau; Mourad Ben Ayed
Journal:  J Autoimmun       Date:  2005-06       Impact factor: 7.094

3.  Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5.

Authors:  E H Niks; J B M Kuks; B O Roep; G W Haasnoot; W Verduijn; B E P B Ballieux; M H De Baets; A Vincent; J J G M Verschuuren
Journal:  Neurology       Date:  2006-06-13       Impact factor: 9.910

4.  Epidemiologic evidence for a changing natural history of myasthenia gravis.

Authors:  L H Phillips; J C Torner
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

5.  Seronegative myasthenia gravis: disease severity and prognosis.

Authors:  F Romi; J A Aarli; N E Gilhus
Journal:  Eur J Neurol       Date:  2005-06       Impact factor: 6.089

6.  Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1. Relation to clinical parameters in 250 patients.

Authors:  P C Limburg; T H The; E Hummel-Tappel; H J Oosterhuis
Journal:  J Neurol Sci       Date:  1983-03       Impact factor: 3.181

7.  Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.

Authors:  Amelia Evoli; Pietro A Tonali; Luca Padua; Mauro Lo Monaco; Flavia Scuderi; Anna P Batocchi; Mariapaola Marino; Emanuela Bartoccioni
Journal:  Brain       Date:  2003-06-23       Impact factor: 13.501

8.  Clinical aspects of MuSK antibody positive seronegative MG.

Authors:  D B Sanders; K El-Salem; J M Massey; J McConville; A Vincent
Journal:  Neurology       Date:  2003-06-24       Impact factor: 9.910

9.  The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland.

Authors:  Paul W Wirtz; Marianne G Nijnuis; Mohammad Sotodeh; Luc N A Willems; Joey J Brahim; Hein Putter; Axel R Wintzen; Jan J Verschuuren
Journal:  J Neurol       Date:  2003-06       Impact factor: 4.849

10.  Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.

Authors:  John McConville; Maria Elena Farrugia; David Beeson; Uday Kishore; Richard Metcalfe; John Newsom-Davis; Angela Vincent
Journal:  Ann Neurol       Date:  2004-04       Impact factor: 10.422

  10 in total
  17 in total

Review 1.  A systematic review of population based epidemiological studies in Myasthenia Gravis.

Authors:  Aisling S Carr; Chris R Cardwell; Peter O McCarron; John McConville
Journal:  BMC Neurol       Date:  2010-06-18       Impact factor: 2.474

Review 2.  The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.

Authors:  Inga Koneczny; Judith Cossins; Angela Vincent
Journal:  J Anat       Date:  2013-03-04       Impact factor: 2.610

Review 3.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

4.  The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates.

Authors:  W Pascale ter Beek; Pilar Martínez-Martínez; Mario Losen; Marc H de Baets; Axel R Wintzen; Jan J G M Verschuuren; Erik H Niks; Sjoerd G van Duinen; Angela Vincent; Peter C Molenaar
Journal:  Am J Pathol       Date:  2009-09-10       Impact factor: 4.307

5.  Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis.

Authors:  Pedro M Rodríguez Cruz; Michal Al-Hajjar; Saif Huda; Leslie Jacobson; Mark Woodhall; Sandeep Jayawant; Camilla Buckley; David Hilton-Jones; David Beeson; Angela Vincent; Maria Isabel Leite; Jacqueline Palace
Journal:  JAMA Neurol       Date:  2015-06       Impact factor: 18.302

6.  Fatigue in myasthenia gravis: risk factors and impact on quality of life.

Authors:  Sarah Hoffmann; Johanna Ramm; Ulrike Grittner; Siegfried Kohler; Jana Siedler; Andreas Meisel
Journal:  Brain Behav       Date:  2016-08-02       Impact factor: 2.708

7.  Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.

Authors:  Shin Joong Oh
Journal:  J Clin Neurol       Date:  2009-06-30       Impact factor: 3.077

8.  An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts.

Authors:  M I Boldingh; L Dekker; A H Maniaol; C Brunborg; A F Lipka; E H Niks; J J G M Verschuuren; C M E Tallaksen
Journal:  Health Qual Life Outcomes       Date:  2015-08-01       Impact factor: 3.186

Review 9.  Myasthenia gravis: a clinical-immunological update.

Authors:  Sophie Binks; Angela Vincent; Jacqueline Palace
Journal:  J Neurol       Date:  2015-12-24       Impact factor: 4.849

Review 10.  Complicating autoimmune diseases in myasthenia gravis: a review.

Authors:  Aliona Nacu; Jintana Bunpan Andersen; Vitalie Lisnic; Jone Furlund Owe; Nils Erik Gilhus
Journal:  Autoimmunity       Date:  2015-04-27       Impact factor: 2.815

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.